Domenica Megalizzi

Dr. Domenica Megalizzi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2024 in Genes
Verified
Journal Article
Open access
PDF file
GCGiulia Calvino
Giulia Calvino
CPCristina Peconi
Cristina Peconi
CSClaudia Strafella
Claudia Strafella
GTGiulia Trastulli
Giulia Trastulli
Domenica MegalizziDomenica Megalizzi
Domenica Megalizzi
EGEmiliano Giardina
Emiliano Giardina
Recent advancements in Next-Generation Sequencing (NGS) technologies have revolutionized genomic research, presenting unprecedented opportunities for personalized medicine and population genetics. However, issues such as data silos, privacy concerns, and regulatory challenges hinder large-scale data integration and collaboration. Federated Learning (FL) has emerged as a transformative solution, enabling decentralized data analysis while preserving privacy and complying with regulations such as the General Data Protection Regulation (GDPR). This review explores the potential use of FL in genomics, detailing its methodology, including local model training, secure aggregation, and iterative improvement. Key challenges, such as heterogeneous data integration and cybersecurity risks, are examined alongside regulations like GDPR. In conclusion, successful implementations of FL in global and national initiatives demonstrate its scalability and role in supporting collaborative research. Finally, we discuss future directions, including AI integration and the necessity of education and training, to fully harness the potential of FL in advancing precision medicine and global health initiatives.

28 March 2024 in Genes
Verified
Journal Article
Open access
PDF file
SZStefania Zampatti
Stefania Zampatti
CPCristina Peconi
Cristina Peconi
Domenica MegalizziDomenica Megalizzi
Domenica Megalizzi
GCGiulia Calvino
Giulia Calvino
GTGiulia Trastulli
Giulia Trastulli
EGEmiliano Giardina
Emiliano Giardina
Artificial intelligence (AI) is rapidly transforming the field of medicine, announcing a new era of innovation and efficiency. Among AI programs designed for general use, ChatGPT holds a prominent position, using an innovative language model developed by OpenAI. Thanks to the use of deep learning techniques, ChatGPT stands out as an exceptionally viable tool, renowned for generating human-like responses to queries. Various medical specialties, including rheumatology, oncology, psychiatry, internal medicine, and ophthalmology, have been explored for ChatGPT integration, with pilot studies and trials revealing each field’s potential benefits and challenges. However, the field of genetics and genetic counseling, as well as that of rare disorders, represents an area suitable for exploration, with its complex datasets and the need for personalized patient care. In this review, we synthesize the wide range of potential applications for ChatGPT in the medical field, highlighting its benefits and limitations. We pay special attention to rare and genetic disorders, aiming to shed light on the future roles of AI-driven chatbots in healthcare. Our goal is to pave the way for a healthcare system that is more knowledgeable, efficient, and centered around patient needs.

11 June 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
GCGiulia Calvino
Giulia Calvino
JFJuliette Farro
Juliette Farro
SZStefania Zampatti
Stefania Zampatti
CPCristina Peconi
Cristina Peconi
Domenica MegalizziDomenica Megalizzi
Domenica Megalizzi
EGEmiliano Giardina
Emiliano Giardina
The increasing burden of cancer globally necessitates innovative approaches for diagnosis, prognosis, and treatment. This article explores the transformative impact of genomics and artificial intelligence (AI) in precision oncology, addressing how their convergence is reshaping cancer care and its challenges. Methods: This review synthesizes current research on the applications of genomics, including next-generation sequencing, and AI, such as machine learning and deep learning, across the cancer care continuum. It examines their roles in identifying genetic variants, assessing cancer risk, guiding targeted therapies and immunotherapy, predicting treatment response, and enabling early detection through liquid biopsies. Results: Genomics and AI are revolutionizing oncology by enabling personalized treatment strategies, improving early detection, and overcoming drug resistance. AI enhances the interpretation of complex genomic data, facilitates drug repurposing, and accelerates the development of novel therapeutics. However, challenges remain regarding data standardization, interpretability, bias in AI algorithms, and ethical considerations. Conclusions: The integration of genomics and AI holds immense potential to advance precision oncology, offering more effective, equitable, and sustainable cancer care. Addressing current challenges and fostering interdisciplinary training will be crucial to fully harness these technologies and redefine oncology practice.

29 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
VCValerio Caputo
Valerio Caputo
Domenica MegalizziDomenica Megalizzi
Domenica Megalizzi
CFCarlo Fabrizio
Carlo Fabrizio
ATAndrea Termine
Andrea Termine
LCLuca Colantoni
Luca Colantoni
CSClaudia Strafella
Claudia Strafella
Despite the knowledge of the main mechanisms involved in facioscapulohumeral muscular dystrophy (FSHD), the high heterogeneity and variable penetrance of the disease complicate the diagnosis, characterization and genotype–phenotype correlation of patients and families, raising the need for further research and data. Thus, the present review provides an update of the main molecular aspects underlying the complex architecture of FSHD, including the genetic factors (related to D4Z4 repeated units and FSHD-associated genes), epigenetic elements (D4Z4 methylation status, non-coding RNAs and high-order chromatin interactions) and gene expression profiles (FSHD transcriptome signatures both at bulk tissue and single-cell level). In addition, the review will also describe the methods currently available for investigating the above-mentioned features and how the resulting data may be combined with artificial-intelligence-based pipelines, with the purpose of developing a multifunctional tool tailored to enhancing the knowledge of disease pathophysiology and progression and fostering the research for novel treatment strategies, as well as clinically useful biomarkers. In conclusion, the present review highlights how FSHD should be regarded as a disease characterized by a molecular spectrum of genetic and epigenetic factors, whose alteration plays a differential role in DUX4 repression and, subsequently, contributes to determining the FSHD phenotype.

18 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
VCValerio Caputo
Valerio Caputo
Domenica MegalizziDomenica Megalizzi
Domenica Megalizzi
CFCarlo Fabrizio
Carlo Fabrizio
ATAndrea Termine
Andrea Termine
LCLuca Colantoni
Luca Colantoni
CSClaudia Strafella
Claudia Strafella
The study describes a protocol for methylation analysis integrated with Machine Learning (ML) algorithms developed to classify Facio-Scapulo-Humeral Dystrophy (FSHD) subjects. The DNA methylation levels of two D4Z4 regions (DR1 and DUX4-PAS) were assessed by an in-house protocol based on bisulfite sequencing and capillary electrophoresis, followed by statistical and ML analyses. The study involved two independent cohorts, namely a training group of 133 patients with clinical signs of FSHD and 150 healthy controls (CTRL) and a testing set of 27 FSHD patients and 25 CTRL. As expected, FSHD patients showed significantly reduced methylation levels compared to CTRL. We utilized single CpG sites to develop a ML pipeline able to discriminate FSHD subjects. The model identified four CpGs sites as the most relevant for the discrimination of FSHD subjects and showed high metrics values (accuracy: 0.94, sensitivity: 0.93, specificity: 0.96). Two additional models were developed to differentiate patients with lower D4Z4 size and patients who might carry pathogenic variants in FSHD genes, respectively. Overall, the present model enables an accurate classification of FSHD patients, providing additional evidence for DNA methylation as a powerful disease biomarker that could be employed for prioritizing subjects to be tested for FSHD.

27 December 2024 in Genes
Verified
Journal Article
Open access
PDF file
SZStefania Zampatti
Stefania Zampatti
JFJuliette Farro
Juliette Farro
CPCristina Peconi
Cristina Peconi
RCRaffaella Cascella
Raffaella Cascella
CSClaudia Strafella
Claudia Strafella
EGEmiliano Giardina
Emiliano Giardina
Background/Objectives: Artificial intelligence and large language models like ChatGPT and Google’s Gemini are promising tools with remarkable potential to assist healthcare professionals. This study explores ChatGPT and Gemini’s potential utility in assisting clinicians during the first evaluation of patients with suspected neurogenetic disorders. Methods: By analyzing the model’s performance in identifying relevant clinical features, suggesting differential diagnoses, and providing insights into possible genetic testing, this research seeks to determine whether these AI tools could serve as a valuable adjunct in neurogenetic assessments. Ninety questions were posed to ChatGPT (Versions 4o, 4, and 3.5) and Gemini: four questions about clinical diagnosis, seven about genetic inheritance, estimable recurrence risks, and available tests, and four questions about patient management, each for six different neurogenetic rare disorders (Hereditary Spastic Paraplegia type 4 and type 7, Huntington Disease, Fragile X-associated Tremor/Ataxia Syndrome, Becker Muscular Dystrophy, and FacioScapuloHumeral Muscular Dystrophy). Results: According to the results of this study, GPT chatbots demonstrated significantly better performance than Gemini. Nonetheless, all AI chatbots showed notable gaps in diagnostic accuracy and a concerning level of hallucinations. Conclusions: As expected, these tools can empower clinicians in assessing neurogenetic disorders, yet their effective use demands meticulous collaboration and oversight from both neurologists and geneticists.